Efficacy of Zolmitriptan (Zomig) in the Treatment of Migraines in Adolescents

Summary

The purpose of this study is to evaluate the effectiveness and safety of Zolmitriptan (Zomig) nasal spray, 5.0 mg, compared with placebo (inactive drug) for 2 migraine headaches over a 3-month period in adolescent patients (aged 12 to 17 years) with migraine headaches

Timeline

Start

2003-09

Primary completion

—

Completion

2004-10

Drugs

Indications